Background
Factor VIII (FVIII) is a heterodimer consisting of a heavy chain (ranging in mass from 90 to 200 kDa) bound via metal ions to a light chain (80 kDa). In plasma, FVIII circulates in an inactive form bound to von Willebrand factor. Following activation by factor Xa or thrombin, factor VIIIa can function as cofactor for the enzyme factor IXa in the activation of factor X in the presence of phospholipid and Ca2+. Absent or defective FVIII is the cause of the X-linked recessive bleeding disorder hemophilia A. GMA-8008 (also known as 1B5 or 1B5.1B)1 recognizes the C2 domain of FVIII, inhibits FVIII activation by thrombin or factor Xa, but does not inhibit the binding of FVIII to phospholipid membranes1. It is suitable for ELISA and bio-layer interferometry pairing experiments, as well as surface plasmon resonance.2,3
More Information
Description
- Species Reactivity:Human
- Source:Murine
- Specificity:C2 domain
- Immunogen:B-domain deleted recombinant Human Factor VIII
- Isotype:IgG2a
Application
- ELISA:Binds the C2 domain of recombinant human factor VIII in solid-phase ELISA.
- Immunoblotting:Not recommended.
- Inhibition:Inhibitory in aPTT clotting assay.1
Data
Antibody References
- S.L. Meeks et al. (2007). Blood. 110(13):4234-4242.
- P.T. Nguyen et al. (2014). Blood. 123(17):2732-2739.
- N.C. Leksa et al. (2017). J Thromb Haemost. 15(6):1167–1179.
- S. Krishnamoorthy et al. (2016). Cell Immunol. 301:30-39.
- J.C. Lin et al. (2015). PLOS ONE. 10(1):1-19.
- G.S. Pandey et al. (2013). Nat Med. 19(10):1318–1324.
$265.00 – $660.00